STOCK TITAN

Healthier Choices 2026 nine-month sales fall to $76

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Healthier Choices Management Corp. (HCMC) reported nine-month net sales of $76, versus $2,979 in 2025, and a net loss of $1,026,977, compared with $6,251,586. Operating expenses were $1,352,731 versus $6,235,686, while net cash used in operations was $645,421 versus $3,058,181.

At September 30, 2026, HCMC had $82,151 in cash, $1.7 million of negative working capital and $1,425,000 of outstanding debt principal. Up to $4.5 million remained available under its Sabby revolving facility, subject to the agreement; it matures December 31, 2026, unless extended at the lender’s sole discretion. Management believes available resources can meet obligations and capital needs for at least 12 months from issuance, but says the company remains highly dependent on additional financing and its plans may not succeed.

Quitcubes launched in the fourth quarter after a delay; initial sales were de minimis and below management’s expectations. HCMC recorded an $89,919 impairment to write off its patents. Management also concluded its financial-reporting and disclosure controls were ineffective as of September 30, citing material weaknesses in segregation of duties and IT controls, and described remediation work.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 3 points

How the balance works

Positive

  • Moderate pointNine-month net loss was $1,026,977, versus $6,251,586 in 2025.
  • Moderate pointOperating cash use was $645,421, versus $3,058,181 in 2025.

Negative

  • Major pointMaterial weaknesses made financial-reporting controls ineffective as of September 30, 2026.
  • Moderate pointNine-month sales were $76, versus $2,979 in 2025.
  • Moderate pointCash was $82,151 against $1.7 million of negative working capital at September 30, 2026.

Filing Explained

The vendor settlement issued 2 billion common shares; Pinz financing and warrants permit further issuance, while Series E preferred is fully redeemed.

This Form 10-Q reports HCMC’s quarter ended September 30, 2026. By quarter-end, the company had redeemed all 1,111 Series E preferred shares for $1,055,545, leaving none outstanding. The filing reports 527,156,418,606 common shares outstanding as of November 13, 2026.

The vendor debt settlement included issuance of 2 billion common shares and an $875,000 non-interest-bearing note. The note has no fixed maturity and becomes due if specified triggers occur, including an equity financing of at least $4 million, a change of control, the CEO leaving the role, or cash reaching $2 million.

HCMC received $50,000 from Pinz under a convertible note bearing 12% annual interest and maturing May 5, 2030. The holder may convert principal and accrued interest at $0.00009 per share, subject to a 9.9% beneficial-ownership cap. The filing estimates approximately 555.6 million shares for conversion of principal alone. HCMC also issued a warrant to purchase 250 million common shares. If conversion or warrant exercise results in new shares, the share count increases and existing holders’ ownership percentages decrease, absent offsetting changes.

Separately, after the consulting agreement ended on September 30, 2026, 2.5 billion warrants remained vested and outstanding; the unvested tranches were forfeited.

Nine-month net sales $76 Nine months ended September 30, 2026; $2,979 in 2025
Nine-month net loss $1,026,977 loss Nine months ended September 30, 2026; $6,251,586 loss in 2025
Net cash used in operating activities $645,421 Nine months ended September 30, 2026; $3,058,181 used in 2025
Cash and cash equivalents $82,151 As of September 30, 2026
Negative working capital $1.7 million As of September 30, 2026
Outstanding debt principal $1,425,000 As of September 30, 2026
Remaining Sabby facility availability Up to $4.5 million Available for future advances, subject to the loan agreement
Patent impairment charge $89,919 Recorded in the third quarter of 2026 to write off the remaining net carrying value of patents
going concern financial
"going concern and management’s plans"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
negative working capital financial
"negative working capital of $1.7 million"
Negative working capital happens when a company’s short-term obligations (bills, supplier invoices, debt coming due) exceed its short-term resources (cash, money owed by customers, sellable inventory). For investors it signals how easily a business can meet immediate bills — it can be a warning sign of cash stress or, in some models, an efficient operation that collects cash faster than it pays suppliers; think of a household that consistently has to borrow before payday versus one that gets paid in advance.
unamortized debt issuance costs financial
"unamortized debt issuance costs and discounts"
beneficial ownership cap financial
"subject to a 9.9% beneficial ownership cap"
A beneficial ownership cap is a rule that limits how much of a company a single investor or related group can effectively control, even if legal ownership could be higher. Think of it as a speed limit for ownership that prevents any one party from accumulating a controlling stake; it matters to investors because it affects takeover risk, voting power, dilution, and potential returns by shaping who can influence corporate decisions.
anti-dilutive financial
"all potentially dilutive securities are anti-dilutive"
A claim, security feature, or action described as anti-dilutive prevents or does not cause a reduction in existing shareholders’ per-share values when additional shares could be issued. For example, certain convertible securities or corporate actions are treated as anti-dilutive for earnings-per-share calculations if including them would raise EPS rather than lower it; investors watch this because it affects reported per-share metrics, ownership percentages, and valuation comparisons, like keeping pie slices the same size instead of making them smaller.
Pre-Funded Warrants financial
"granted the Consultant Pre-Funded Warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were HCMC’s sales and net loss for the first nine months of 2026?

Net sales were $76 for the nine months ended September 30, 2026, compared with $2,979 in 2025. HCMC reported a net loss of $1,026,977, compared with a $6,251,586 net loss in 2025.

How much could HCMC still draw under its Sabby loan?

As of September 30, 2026, up to $4.5 million remained available for future advances under the Sabby facility, subject to its terms and conditions. The facility matures December 31, 2026, unless extended at the lender’s sole discretion.

What are the terms of HCMC’s $50,000 convertible note?

The note from Pinz Capital Special Opportunities Fund, LP bears interest at 12% per annum and matures May 5, 2030. Principal and interest are due in ten equal monthly installments beginning on the third anniversary of issuance, subject to earlier conversion. Conversion is at $0.00009 per share, subject to a 9.9% beneficial ownership cap; the related warrant covers 250,000,000 common shares.

Who handles marketing and manufacturing for HCMC’s Quitcubes product line?

The third-party distributor is responsible for marketing, customer fulfillment and website management, while HCMC is responsible for manufacturing. The launch, originally anticipated in the first quarter of 2026, was delayed while HCMC established the operational infrastructure for the agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false Q3 --12-31 0000844856 0000844856 2026-01-01 2026-09-30 0000844856 2026-11-13 0000844856 2026-09-30 0000844856 2025-12-31 0000844856 2026-07-01 2026-09-30 0000844856 2025-07-01 2025-09-30 0000844856 2025-01-01 2025-09-30 0000844856 us-gaap:PreferredStockMember HCMC:SeriesEConvertiblePreferredStockMember 2026-06-30 0000844856 us-gaap:CommonStockMember 2026-06-30 0000844856 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0000844856 us-gaap:RetainedEarningsMember 2026-06-30 0000844856 2026-06-30 0000844856 us-gaap:PreferredStockMember HCMC:SeriesERedeemableConvertiblePreferredStockMember 2026-06-30 0000844856 us-gaap:PreferredStockMember HCMC:SeriesEConvertiblePreferredStockMember 2025-06-30 0000844856 us-gaap:CommonStockMember 2025-06-30 0000844856 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000844856 us-gaap:RetainedEarningsMember 2025-06-30 0000844856 2025-06-30 0000844856 us-gaap:PreferredStockMember HCMC:SeriesERedeemableConvertiblePreferredStockMember 2025-06-30 0000844856 us-gaap:PreferredStockMember HCMC:SeriesEConvertiblePreferredStockMember 2025-12-31 0000844856 us-gaap:CommonStockMember 2025-12-31 0000844856 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0000844856 us-gaap:RetainedEarningsMember 2025-12-31 0000844856 us-gaap:PreferredStockMember HCMC:SeriesERedeemableConvertiblePreferredStockMember 2025-12-31 0000844856 us-gaap:PreferredStockMember HCMC:SeriesEConvertiblePreferredStockMember 2024-12-31 0000844856 us-gaap:CommonStockMember 2024-12-31 0000844856 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000844856 us-gaap:RetainedEarningsMember 2024-12-31 0000844856 2024-12-31 0000844856 us-gaap:PreferredStockMember HCMC:SeriesERedeemableConvertiblePreferredStockMember 2024-12-31 0000844856 us-gaap:PreferredStockMember HCMC:SeriesEConvertiblePreferredStockMember 2026-07-01 2026-09-30 0000844856 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0000844856 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0000844856 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0000844856 us-gaap:PreferredStockMember HCMC:SeriesERedeemableConvertiblePreferredStockMember 2026-07-01 2026-09-30 0000844856 us-gaap:PreferredStockMember HCMC:SeriesEConvertiblePreferredStockMember 2025-07-01 2025-09-30 0000844856 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0000844856 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0000844856 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0000844856 us-gaap:PreferredStockMember HCMC:SeriesEConvertiblePreferredStockMember 2026-01-01 2026-09-30 0000844856 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0000844856 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-09-30 0000844856 us-gaap:RetainedEarningsMember 2026-01-01 2026-09-30 0000844856 us-gaap:PreferredStockMember HCMC:SeriesERedeemableConvertiblePreferredStockMember 2026-01-01 2026-09-30 0000844856 us-gaap:PreferredStockMember HCMC:SeriesEConvertiblePreferredStockMember 2025-01-01 2025-09-30 0000844856 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0000844856 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0000844856 us-gaap:RetainedEarningsMember 2025-01-01 2025-09-30 0000844856 us-gaap:PreferredStockMember HCMC:SeriesEConvertiblePreferredStockMember 2026-09-30 0000844856 us-gaap:CommonStockMember 2026-09-30 0000844856 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0000844856 us-gaap:RetainedEarningsMember 2026-09-30 0000844856 us-gaap:PreferredStockMember HCMC:SeriesERedeemableConvertiblePreferredStockMember 2026-09-30 0000844856 us-gaap:PreferredStockMember HCMC:SeriesEConvertiblePreferredStockMember 2025-09-30 0000844856 us-gaap:CommonStockMember 2025-09-30 0000844856 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0000844856 us-gaap:RetainedEarningsMember 2025-09-30 0000844856 2025-09-30 0000844856 us-gaap:PreferredStockMember HCMC:SeriesERedeemableConvertiblePreferredStockMember 2025-09-30 0000844856 HCMC:SabbyLoanAgreementMember 2026-03-27 0000844856 HCMC:SabbyLoanAgreementMember 2026-03-27 2026-03-27 0000844856 HCMC:PinzCapitalSpecialOpportunitiesFundLPMember 2026-06-26 2026-06-26 0000844856 HCMC:PinzCapitalSpecialOpportunitiesFundLPMember us-gaap:CommonStockMember 2026-06-26 2026-06-26 0000844856 HCMC:PinzCapitalSpecialOpportunitiesFundLPMember 2026-06-26 0000844856 HCMC:SabbyLoanAgreementMember 2026-06-26 2026-06-26 0000844856 us-gaap:FurnitureAndFixturesMember 2026-09-30 0000844856 us-gaap:FurnitureAndFixturesMember 2025-12-31 0000844856 HCMC:ComputerHardwareAndEquipmentMember 2026-09-30 0000844856 HCMC:ComputerHardwareAndEquipmentMember 2025-12-31 0000844856 HCMC:OtherFixedAssetsMember 2026-09-30 0000844856 HCMC:OtherFixedAssetsMember 2025-12-31 0000844856 us-gaap:PatentsMember 2026-09-30 0000844856 us-gaap:PatentsMember 2025-12-31 0000844856 2024-11-07 0000844856 2024-11-07 2024-11-07 0000844856 2025-04-11 2025-04-11 0000844856 HCMC:SabbyLoanAgreementMember 2026-09-30 0000844856 HCMC:SabbyLoanAgreementMember 2026-01-01 2026-09-30 0000844856 us-gaap:LineOfCreditMember 2026-07-01 2026-09-30 0000844856 us-gaap:LineOfCreditMember 2025-07-01 2025-09-30 0000844856 us-gaap:LineOfCreditMember 2026-01-01 2026-09-30 0000844856 us-gaap:LineOfCreditMember 2025-01-01 2025-09-30 0000844856 HCMC:DebtAgreementMember 2026-02-01 0000844856 HCMC:PinzCapitalSpecialOpportunitiesFundLPMember us-gaap:CommonStockMember 2026-06-26 0000844856 HCMC:PinzCapitalSpecialOpportunitiesFundLPMember us-gaap:CommonStockMember 2026-06-26 2026-06-26 0000844856 HCMC:PinzCapitalSpecialOpportunitiesFundLPMember 2026-09-30 0000844856 HCMC:PinzCapitalSpecialOpportunitiesFundLPMember 2026-01-01 2026-09-30 0000844856 HCMC:SeriesEConvertiblePreferredStockMember HCMC:SecuritiesPurchaseAgreementMember 2022-08-18 0000844856 HCMC:SeriesEConvertiblePreferredStockMember HCMC:SecuritiesPurchaseAgreementMember 2022-08-18 2022-08-18 0000844856 us-gaap:SeriesEPreferredStockMember HCMC:SecuritiesPurchaseAgreementMember 2022-08-18 0000844856 us-gaap:SeriesEPreferredStockMember HCMC:FirstAmendmentToSecuritiesPurchaseAgreementMember 2023-03-01 0000844856 us-gaap:SeriesEPreferredStockMember HCMC:SecondAmendmentToSecuritiesPurchaseAgreementMember 2023-05-15 2023-05-15 0000844856 us-gaap:SeriesEPreferredStockMember HCMC:ThirdAmendmentToSecuritiesPurchaseAgreementMember 2023-10-30 2023-10-30 0000844856 us-gaap:SeriesEPreferredStockMember 2026-09-01 0000844856 2026-09-01 2026-09-01 0000844856 us-gaap:SeriesEPreferredStockMember 2026-01-01 2026-09-30 0000844856 us-gaap:StockOptionMember 2026-07-01 2026-09-30 0000844856 us-gaap:StockOptionMember 2026-01-01 2026-09-30 0000844856 us-gaap:StockOptionMember 2025-07-01 2025-09-30 0000844856 us-gaap:StockOptionMember 2025-01-01 2025-09-30 0000844856 HCMC:WarrantsMember HCMC:ActiveVenturesLLCPreFundedWarrantsMember us-gaap:CommonStockMember 2026-04-24 2026-04-24 0000844856 HCMC:WarrantsMember HCMC:ActiveVenturesLLCPreFundedWarrantsMember us-gaap:CommonStockMember 2026-04-24 0000844856 HCMC:WarrantsMember HCMC:ActiveVenturesLLCPreFundedWarrantsMember us-gaap:CommonStockMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2026-04-24 2026-04-24 0000844856 HCMC:WarrantsMember HCMC:ActiveVenturesLLCPreFundedWarrantsMember us-gaap:CommonStockMember 2026-04-10 2026-04-10 0000844856 us-gaap:WarrantMember HCMC:ActiveVenturesLLCPreFundedWarrantsMember 2026-07-01 2026-09-30 0000844856 us-gaap:WarrantMember HCMC:ActiveVenturesLLCPreFundedWarrantsMember 2026-01-01 2026-09-30 0000844856 HCMC:WarrantsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2026-01-01 2026-09-30 0000844856 HCMC:HealthyChoiceWellnessCorpMember 2025-12-31 2025-12-31 0000844856 HCMC:HealthyChoiceWellnessCorpMember 2025-12-31 0000844856 HCMC:SettlementAgreementMember 2026-02-01 0000844856 HCMC:SettlementAgreementMember 2026-02-01 2026-02-01 0000844856 us-gaap:PreferredStockMember 2026-01-01 2026-09-30 0000844856 us-gaap:PreferredStockMember 2025-01-01 2025-09-30 0000844856 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0000844856 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0000844856 us-gaap:RestrictedStockMember 2026-01-01 2026-09-30 0000844856 us-gaap:RestrictedStockMember 2025-01-01 2025-09-30 0000844856 HCMC:PreFundedWarrantsMember 2026-01-01 2026-09-30 0000844856 HCMC:PreFundedWarrantsMember 2025-01-01 2025-09-30 0000844856 2023-12-31 0000844856 2024-06-30 0000844856 2025-05-31 2025-05-31 0000844856 us-gaap:RelatedPartyMember 2026-09-30 0000844856 us-gaap:RelatedPartyMember 2025-12-31 0000844856 2025-01-01 2025-12-31 0000844856 HCMC:TerminationofTransitionServicesAgreementMember 2026-07-01 2026-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

Or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____ to _____

 

Commission file number: 001-36469

 

HEALTHIER CHOICES MANAGEMENT CORP.

(Exact name of Registrant as specified in its charter)

 

Delaware   84-1070932
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)
     
3800 North 28th Way    
Hollywood, Florida   33020
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: 305-600-5004

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

☒ Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

 

☒ Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
  Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

☐ Yes ☒ No

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   HCMC   OTC Pink Marketplace

 

As of November 13, 2026, there were 527,156,418,606 shares of the registrant’s common stock, par value $0.0001 per share, outstanding.

 

 

 

 

 

 

TABLE OF CONTENTS

 

  PAGE
   
PART I FINANCIAL INFORMATION 3
   
ITEM 1. Financial Statements 3
   
Condensed Consolidated Balance Sheets as of September 30, 2026 (Unaudited) and December 31, 2025 3
   
Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited) 4
   
Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equity for the Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited) 5
   
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2026 and 2025 (Unaudited) 7
   
Notes to Condensed Consolidated Financial Statements (Unaudited) 8
   
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 17
   
ITEM 3. Quantitative and Qualitative Disclosures about Market Risk 21
   
ITEM 4. Controls and Procedures 21
   
PART II OTHER INFORMATION 23
   
ITEM 1. Legal Proceedings 23
   
ITEM 1A. Risk Factors 23
   
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 23
   
ITEM 3. Defaults Upon Senior Securities 23
   
ITEM 4. Mine Safety Disclosures 23
   
ITEM 5. Other Information 23
   
ITEM 6. Exhibits 23
   
Signatures 25
   
Exhibit 31.1  
   
Exhibit 31.2  
   
Exhibit 32.1  
   
Exhibit 32.2  

 

2

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

HEALTHIER CHOICES MANAGEMENT CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

  

September 30, 2026

(Unaudited)

   December 31, 2025 
         
ASSETS          
CURRENT ASSETS          
Cash and cash equivalents  $82,151   $1,140,488 
Accounts receivable, net   -    199 
Inventories   36,737    36,148 
Prepaid expenses and vendor deposits   50,683    62,891 
Restricted cash   -    100,000 
TOTAL CURRENT ASSETS   169,571    1,339,726 
           
Property, plant, and equipment, net of accumulated depreciation   1,937    7,789 
Intangible assets, net of accumulated amortization   -    119,026 
Right of use asset – operating lease, net   -    1,329 
TOTAL ASSETS  $171,508   $1,467,870 
           
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT          
CURRENT LIABILITIES          
Accounts payable and accrued expenses  $526,156   $1,588,935 
Loan payable, current   1,372,691    - 
Operating lease liability, current   -    1,329 
Due to related party   10,720    - 
TOTAL CURRENT LIABILITIES   1,909,567    1,590,264 
           
Loan payable, net of current portion   26,537    - 
TOTAL LIABILITIES   1,936,104    1,590,264 
           
COMMITMENTS AND CONTINGENCIES (SEE NOTE 9)          
           
CONVERTIBLE PREFERRED STOCK          
Series E redeemable convertible preferred stock, $1,000 par value per share, 14,722 shares authorized, 0 and 1,111 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively; aggregate liquidation preference of $0 and $1.1 million as of September 30, 2026 and December 31, 2025, respectively.   -    1,111,100 
STOCKHOLDERS’ DEFICIT          
Common Stock, $0.0001 par value per share, 750,000,000,000 shares authorized; 527,156,418,606 and 525,156,418,606 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively.   52,715,642    52,515,642 
Additional paid-in capital   28,600,279    28,304,404 
Accumulated deficit   (83,080,517)   (82,053,540)
TOTAL STOCKHOLDERS’ DEFICIT   (1,764,596)   (1,233,494)
           
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT  $171,508   $1,467,870 

 

See notes to unaudited condensed consolidated financial statements

 

3

 

 

HEALTHIER CHOICES MANAGEMENT CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   2026   2025   2026   2025 
   Three Months Ended September 30,   Nine Months Ended September 30, 
   2026   2025   2026   2025 
SALES, NET  $76   $199   $76   $2,979 
                     
COST OF SALES   18    -    18    25,312 
                     
GROSS PROFIT   58    199    58    (22,333)
                     
OPERATING EXPENSES   302,339    2,085,196    1,352,731    6,235,686 
                     
RECLASSIFICATION OF PAYROLL EXPENSE – TSA TERMINATION   -    -    (328,373)   - 
                     
LOSS FROM OPERATIONS   (302,281)   (2,084,997)   (1,024,300)   (6,258,019)
                     
OTHER INCOME (EXPENSE)                    
Loss on disposal of asset   -    -    -    (22,809)
Other (expense) income, net   (136)   -    12,364    3,070 
Interest (expense) income, net   (13,001)   8,884    (15,041)   26,172 
TOTAL OTHER INCOME (EXPENSE), NET   (13,137)   8,884    (2,677)   6,433 
                     
NET LOSS  $(315,418)  $(2,076,113)  $(1,026,977)  $(6,251,586)
                     
NET LOSS PER SHARE-BASIC AND DILUTED  $-   $-   $-   $- 
                     
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING-BASIC AND DILUTED   527,156,418,606    481,266,632,384    526,914,660,364    481,266,632,384 

 

See notes to unaudited condensed consolidated financial statements

 

4

 

 

HEALTHIER CHOICES MANAGEMENT CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

   Shares   Amount   Shares   Amount   Capital   Deficit   Total 
   Series E Redeemable
Convertible
Preferred Stock
   Common Stock  

Additional

Paid In

   Accumulated     
   Shares   Amount   Shares   Amount   Capital   Deficit   Total 
                             
Balance – July 1, 2026- 1,111   $1,111,100    527,156,418,606   $52,715,642   $28,312,529   $(82,765,099)  $(1,736,928)
Series E preferred stock redemption-  (1,111)   (1,111,100)   -    -    55,555    -    55,555 
Value of warrants issued as debt discount-  -    -    -    -    25,000    -    25,000 
Capital contribution from related party   -    -    -    -    207,195    -    207,195 
Net loss-  -    -    -    -    -    (315,418)   (315,418)
Balance – September 30, 2026-  -   $-    527,156,418,606   $52,715,642   $28,600,279   $(83,080,517)  $(1,764,596)

 

  

Series E Convertible

Preferred Stock

   Common Stock  

Additional

Paid-In

   Accumulated     
   Shares   Amount   Shares   Amount   Capital   Deficit   Total 
Balance – July 1, 2025-  1,111   $1,111,100    481,266,632,384   $48,126,663   $27,592,941   $(79,211,068)  $(3,491,464)
Stock-based compensation expense-  -    -    -    -    1,122,583    -    1,122,583 
Net loss-  -    -    -    -    -    (2,076,113)   (2,076,113)
Balance – September 30, 2025-  1,111   $1,111,100    481,266,632,384   $48,126,663   $28,715,524    (81,287,181)  $(4,444,994)

 

5

 

 

HEALTHIER CHOICES MANAGEMENT CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

   Shares   Amount   Shares   Amount   Capital   Deficit   Total 
   Series E Redeemable Convertible           Additional         
   Preferred Stock   Common Stock   Paid In   Accumulated     
   Shares   Amount   Shares   Amount   Capital   Deficit   Total 
Balance – January 1, 2026-  1,111   $1,111,100    525,156,418,606   $52,515,642   $28,304,404   $(82,053,540)  $(1,233,494)
Issuance of common stock for debt settlement-  -    -    2,000,000,000    200,000    -    -    200,000 
Series E preferred stock redemption-  (1,111)   (1,111,100)   -    -    55,555    -    55,555 
Value of warrants issued as debt discount-  -    -    -    -    25,000    -    25,000 
Warrants vested for services-  -    -    -    -    8,125    -    8,125 
Capital contribution from related party   -    -    -    -    

207,195

    -    

207,195

 
Net loss-  -    -    -    -    -    (1,026,977)   (1,026,977)
Balance – September 30, 2026-  -   $-    527,156,418,606   $52,715,642   $28,600,279   $

(83,080,517

)  $(1,764,596)

 

  

Series E Convertible

Preferred Stock

   Common Stock  

Additional

Paid-In

   Accumulated     
   Shares   Amount   Shares   Amount   Capital   Deficit   Total 
Balance – January 1, 2025-  1,111   $1,111,100    481,266,632,384   $48,126,663   $25,347,774   $(75,035,595)  $(1,561,158)
Stock-based compensation expense-  -    -    -    -    3,367,750    -    3,367,750 
Net loss-  -    -    -    -    -    (6,251,586)   (6,251,586)
Balance – September 30, 2025-  1,111   $1,111,100    481,266,632,384   $48,126,663   $28,715,524   $(81,287,181)  $(4,444,994)

 

See notes to unaudited condensed consolidated financial statements

 

6

 

 

HEALTHIER CHOICES MANAGEMENT CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   2026   2025 
   Nine Months Ended September 30, 
   2026   2025 
CASH FLOWS FROM OPERATING ACTIVITIES          
Net loss from continuing operations  $(1,026,977)  $(6,251,586)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   34,959    39,313 
Loss on asset disposal   -    22,809 
Warrants vested for services   8,125    - 
Amortization of debt discount   6,599    - 
Amortization of right-of-use asset   -    1,538 
Stock-based compensation expense   -    3,367,751 
Impairment of intangible assets   89,919    - 
Changes in operating assets and liabilities:          
Accounts receivable   199    (199)
Inventories   (589)   2,420 
Prepaid expenses and vendor deposits   12,208    108,261 
Other current assets   -    (4,810)
Other assets   -    780 
Due to related party   217,915    1,428 
Accounts payable and accrued expenses   12,221    (343,567)
Lease liability   -    (2,319)
NET CASH USED IN OPERATING ACTIVITIES   (645,421)   (3,058,181)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Purchases of property and equipment   -    - 
NET CASH USED IN INVESTING ACTIVITIES   -    - 
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Proceeds from loan agreement   492,629    - 
Proceeds from convertible note payable   50,000    - 
Redemption of Series E preferred stock   (1,055,545)   - 
Payment on line of credit   -    (453,232)
Due to related party   -    2,986,211 
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES   (512,916)   2,532,979 
           
NET DECREASE IN CASH, CASH EQUIVALENT AND RESTRICTED CASH   (1,158,337)   (525,202)
           
CASH, CASH EQUIVALENT AND RESTRICTED CASH— BEGINNING OF PERIOD   1,240,488    1,746,799 
CASH, CASH EQUIVALENT AND RESTRICTED CASH — END OF PERIOD  $82,151   $1,221,597 
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION          
Cash paid for interest  $-   $582 
Cash paid for income tax  $-   $- 
NON-CASH INVESTING AND FINANCING ACTIVITIES          
Issuance of promissory note in connection with debt settlement  $875,000   $- 
Issuance of common stock to settle debt  $200,000   $- 
Forgiveness of related party payable (capital contribution)  $

207,195

   $- 

 

See notes to unaudited condensed consolidated financial statements.

 

7

 

 

HEALTHIER CHOICES MANAGEMENT CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

NOTE 1. ORGANIZATION

 

Organization

 

Healthier Choices Management Corp. (the “Company” or “HCMC”) is a holding company focused on monetizing its intellectual property through its wholly owned subsidiary, HCMC Intellectual Property Holdings, LLC. The Company seeks to further monetize its patent suite through development and production of its patented products, including the Q-Cup™ technology and Imitine, licensing and royalty agreements, and enforcement actions against infringers of its intellectual property.

 

The Company administers and intends to augment its intellectual property portfolio via its wholly owned subsidiary, HCMC Intellectual Property Holdings, LLC.

 

The Company continues to promote its patented Q-Cup™ technology directly to consumers in the vaping market. This cutting-edge design includes a small quartz cup that users can fill with cannabis or CBD concentrate. Once placed in a Q-Cup™ Tank or Globe, the cup is heated externally without direct contact with the concentrate. This innovative approach provides greater efficiency and a convenient solution for consumers who vape concentrates for both medicinal and recreational use.

 

In connection with the Company’s strategic initiative to monetize its intellectual property through the development and production of new products, the Company entered into a Distribution Agreement (the “Distribution Agreement”) with a third party distributor on November 27, 2025, to commercialize a new product line utilizing the Company’s NatureTine™ ingredient (the “Quitcubes” product line). Under the Distribution Agreement, the distributor is responsible for marketing, customer fulfillment, and website management, while the Company is responsible for manufacturing the product.

 

The launch of the Quitcubes product line, originally anticipated to commence in the first quarter of 2026, was delayed as the Company worked to establish the necessary operational infrastructure to execute the Distribution Agreement. As a result, the Company recorded no material net sales from the Quitcubes product line for the three and nine months ended September 30, 2026.

 

Subsequent to September 30, 2026, the Company officially launched the Quitcubes product line. However, initial sales during the fourth quarter of 2026 have been de minimis and have not met management’s initial expectations. Management continues to work with the distributor to support the commercial launch and drive product awareness. However, there can be no assurance that the product line will generate material revenue or positive cash flow in the future.

 

Segment Reporting

 

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the operating decision makers, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company operates as a single reportable segment, as the chief operating decision maker (“CODM”, the Company’s Chief Executive Officer, Jeffrey Holman) reviews financial performance and makes decisions on a consolidated basis.

 

8

 

 

NOTE 2. GOING CONCERN AND MANAGEMENT’S PLANS

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern and realization of assets and satisfaction of liabilities in the normal course of business and do not include any adjustments that might result from the outcome of any uncertainties related to our going concern assessment. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values.

 

The Company currently and historically has reported net losses and cash outflows from operations. As of September 30, 2026, the Company had cash and cash equivalents of approximately $0.1 million and negative working capital of $1.7 million. The Company’s liquidity needs through September 30, 2026 have been satisfied through financing agreement with private lenders.

 

On March 27, 2026, the Company entered into a $5 million loan agreement with Sabby Volatility Warrant Master Fund, Ltd. (the “Sabby Loan Agreement”). Concurrently, the Company terminated its prior $5 million credit facility with a private lender. In connection with the Sabby Loan Agreement, the Company received an initial advance of $500,000. The remaining $4.5 million is available to the Company subject to the terms and conditions of the Sabby Loan Agreement.

 

On June 26, 2026, the Company received $50,000 in cash proceeds from Pinz Capital Special Opportunities Fund, LP in connection with a convertible promissory note. The formal loan agreement was executed on July 6, 2026. The note matures on May 5, 2030, bears interest at 12% per annum, with principal and interest due in ten equal monthly installments beginning on the third anniversary of issuance, subject to earlier conversion. The proceeds from this note provided additional liquidity to support the Company’s operations.

 

Management has made plans to reduce certain costs and raise needed capital. The Company had also anticipated that the successful commercial launch of the Quitcubes product line would begin to generate revenue and offset a portion of the Company’s recurring losses. However, as disclosed in Note 1, initial sales during the fourth quarter of 2026 have been de minimis and have not met management’s expectations. Consequently, the Company remains highly dependent on securing additional financing to fund its operations. The success of these plans is dependent upon various factors, foremost being the ability to reduce outside consulting expenses and the ability to secure additional capital from outside investors. There can be no assurance that such plans will be successful.

 

Management believes that the Company’s cash on hand, together with the availability of up to $4.5 million in additional draws under the Sabby Loan Agreement, and the $50,000 in proceeds from the June 26, 2026 convertible note, will enable the Company to meet its obligations and capital requirements for at least the twelve months from the date of this filing. Accordingly, no adjustment has been made to the financial statements to account for this uncertainty.

 

NOTE 3. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Consolidation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Regulation S-X and do not include all the information and disclosures required by GAAP. The Company has made estimates and judgments affecting the amounts reported in the Company’s unaudited condensed consolidated financial statements and the accompanying notes. The actual results experienced by the Company may differ materially from the Company’s estimates. The condensed consolidated financial information is unaudited but reflects all normal adjustments that are, in the opinion of management, necessary to provide a fair statement of results for the interim periods presented.

 

These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 27, 2026. The condensed consolidated balance sheet as of December 31, 2025 was derived from the Company’s audited 2025 financial statements contained in the above referenced Form 10-K. Results of the three and nine months ended September 30, 2026, are not necessarily indicative of the results to be expected for the full year ending December 31, 2026.

 

9

 

 

Significant Accounting Policies

 

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2025 Annual Report.

 

NOTE 4. CONCENTRATIONS

 

Cash, Cash Equivalent and Restricted Cash

 

The Company considers all highly liquid instruments with an original maturity of three months or less, when purchased, to be cash and cash equivalents. The majority of the Company’s cash and cash equivalents are concentrated in one large financial institution, which is in excess of Federal Deposit Insurance Corporation (FDIC) coverage.

 

A summary of the financial institution that had cash, cash equivalent and restricted cash in excess of FDIC limits of $250,000 on September 30, 2026 and December 31, 2025 is presented below:

 

   September 30, 2026   December 31, 2025 
Total cash and cash equivalents in excess of FDIC limits of $250,000  $         -   $880,191 

 

The Company continually monitors its positions with, and the credit quality of, the financial institutions with which it invests, as deposits are held in excess of federally insured limits. The Company has not experienced any losses in such accounts.

 

The following table provides a reconciliation of cash, cash equivalent and restricted cash to amounts shown in unaudited condensed consolidated statements of cash flow:

 

   September 30, 2026   December 31, 2025 
Cash and cash equivalents  $82,151   $1,140,488 
Restricted cash   -    100,000 
Total cash and restricted cash  $82,151   $1,240,488 

 

Restricted Cash

 

As of December 31, 2025, the Company’s restricted cash consisted of $100,000 in cash balances which were restricted as to withdrawal or usage under the August 18, 2022 Securities Purchase Agreement for the purpose of funding any amounts due under the Series E Certificate of Designation upon the redemption of the Series E Preferred Stock. During the nine months ended September 30, 2026, the Company redeemed all remaining outstanding shares of Series E Preferred Stock (see Note 8). As a result, the restriction on these funds was lifted, and the Company had $0 in restricted cash as of September 30, 2026.

 

10

 

 

NOTE 5. PROPERTY AND EQUIPMENT

 

Property and equipment consist of the following:

 

   September 30, 2026   December 31, 2025 
Furniture and fixtures   33,895    33,895 
Computer hardware & equipment   50,522    50,522 
Other fixed assets   8,056    8,056 
Property and equipment, gross   92,473    92,473 
Less: accumulated depreciation and amortization   (90,536)   (84,684)
Total property, plant, and equipment  $1,937   $7,789 

 

The Company incurred approximately $2,000 of depreciation expense for the three months ended September 30, 2026 and 2025, and approximately $6,000 and $7,000 of depreciation expense for the nine months ended September 30, 2026 and 2025, respectively.

 

NOTE 6. INTANGIBLE ASSETS

 

The Company’s intangible assets consist of patents and capitalized legal fees related to the patents. Intangible assets, net are as follows:

 

September 30, 2026 

Useful Lives

(Years)

 

Gross Carrying

Amount

  

Accumulated

Amortization

  

Net

Carrying

Amount

 
Patent  10 years  $397,165   $(397,165)  $        - 
Intangible assets, net     $397,165   $(397,165)  $- 

 

December 31, 2025  Useful Lives
(Years)
  Gross Carrying
Amount
   Accumulated
Amortization
   Net
Carrying
Amount
 
Patent  10 years   397,165    (278,139)   119,026 
Intangible assets, net     $397,165   $(278,139)  $119,026 

 

In connection with the Company’s annual impairment assessment performed during the third quarter of 2026, management determined that the carrying value of the Company’s patents was not recoverable. This conclusion was based on the fact that the Company has not generated material sales from its patented products, and projected undiscounted future cash flows did not support the carrying value of the assets. As a result, the Company recorded an impairment charge of $89,919 to fully write off the remaining net carrying value of its patents. This impairment charge is included in operating expenses in the accompanying condensed consolidated statements of operations and is added back as a non-cash adjustment in the statement of cash flows.

 

Intangible assets are amortized on a straight-line basis over their estimated useful lives. Amortization expense was approximately $10,000 and $11,000 for the three months ended September 30, 2026 and 2025, and $29,000 and $33,000 for the nine months ended September 30, 2026 and 2025, respectively. As of September 30, 2026, the patents are fully impaired and written off; therefore, there is no future annual estimated amortization expense for the years ending December 31, 2026 and beyond.

 

11

 

 

NOTE 7. DEBT

 

Private Lender Credit Facility

 

On November 7, 2024, the Company entered into a $5,000,000 revolving line of credit agreement with a private lender (the “Prior Facility”). The Prior Facility bore interest at 12% per annum, payable quarterly, and was scheduled to mature on April 30, 2026. On April 11, 2025, the Company and the lender amended the agreement to extend the maturity date to December 31, 2026. On March 27, 2026, the Company terminated the Prior Facility. No amounts were outstanding under the Prior Facility at the time of termination.

 

Sabby Volatility Warrant Master Fund, Ltd. Credit Facility

 

On March 27, 2026, the Company entered into a Loan Agreement (the “Sabby Loan Agreement”) with Sabby Volatility Warrant Master Fund, Ltd. (the “Lender”), providing for a $5,000,000 unsecured revolving line of credit. The Sabby Facility matures on December 31, 2026, unless extended at the Lender’s sole discretion. Borrowings under the Sabby Facility bear interest at 12% per annum. Interest is payable on the Maturity Date, together with the outstanding principal balance. The Company may request advances from time to time, subject to the terms and conditions of the Sabby Loan Agreement. In connection with the initial funding under the Sabby Facility, the Company received an advance of $500,000 (the “Initial Advance”).

 

As of September 30, 2026, the outstanding principal balance under the Sabby Facility was $500,000. The remaining $4,500,000 is available for future advances, subject to the terms and conditions of the Sabby Loan Agreement. Interest expense for the three months ended September 30, 2026 was approximately $15,000, compared to approximately $0 for the same period in 2025. Interest expense for the nine months ended September 30, 2026 was approximately $31,000, compared to approximately $0 for the same period in 2025. Interest expense is recognized as incurred based on the outstanding principal balance and the contractual interest rate.

 

Promissory Note

 

On February 1, 2026, the Company entered into a Stock Purchase and Satisfaction of Debt Agreement with a legal vendor to settle outstanding amount in excess of $1.4 million. In connection with this agreement, the Company issued $875,000 promissory note to this legal vendor. The Note is non-interest-bearing and has no fixed maturity date. The principal amount of $875,000 becomes due immediately upon the first occurrence of any of the following events:

 

  ● Equity financing of $4 million or more
  ● Change of control of the Company
  ● The Chief Executive Officer no longer serves in that role
  ● Bankruptcy or dissolution of the Company
  ● The Company has $2 million or more in cash

 

The note is classified as a current liability and recorded at face value. The issuance of the Note was a non-cash financing activity. Accordingly, it has been excluded from the statement of cash flows and disclosed in the supplemental schedule of non-cash investing and financing activities.

 

Convertible Promissory Note

 

On June 26, 2026, the Company received $50,000 in cash proceeds from Pinz Capital Special Opportunities Fund, LP (the “Holder”) in connection with a convertible promissory note. The formal loan agreement was executed on July 6, 2026. The note matures on May 5, 2030 and bears interest at 12% per annum, with principal and interest due in ten equal monthly installments beginning on the third anniversary of issuance, subject to earlier conversion. The Holder may convert principal and accrued interest at any time into common stock at $0.00009 per share, subject to a 9.9% beneficial ownership cap, resulting in approximately 555.6 million shares issuable upon full conversion of principal alone. In connection with the note, the Company also issued the Holder a warrant to purchase 250,000,000 shares of common stock. The note is unsecured and contains customary default provisions, including a share reserve requirement, transfer agent reserve letter, and default interest rate of up to 18% per annum.

 

As of September 30, 2026, the Company’s total outstanding debt principal was $1,425,000. Of this amount, $1,375,000 is classified as current liabilities, consisting of $500,000 outstanding under the Sabby Loan Agreement (maturing December 31, 2026) and an $875,000 promissory note to a legal vendor (due upon the occurrence of certain triggering events). The remaining $50,000 is classified as long-term liabilities, representing the convertible promissory note with Pinz Capital, which matures on May 5, 2030.

 

The total carrying value of the Company’s debt on the accompanying condensed consolidated balance sheets was $1,399,228 as of September 30, 2026 (comprised of $1,372,691 in current liabilities and $26,537 in long-term liabilities). This carrying value is net of approximately $25,772 of unamortized debt issuance costs and discounts. The unamortized balance consists of $23,463 related to the discount on the convertible promissory note with Pinz Capital (arising from the fair value of warrants issued and original issue discount), and $2,309 related to debt issuance costs and discounts on the Company’s other debt instruments. These costs and discounts are being amortized to interest expense over the respective terms of the related debt instruments using the effective interest method.

 

12

 

 

NOTE 8. STOCKHOLDERS’ EQUITY

 

Series E Convertible Preferred Stock

 

On August 18, 2022, the Company entered into a Securities Purchase Agreement (“Purchase Agreement”) pursuant to which the Company sold and issued 14,722 shares of its Series E Redeemable Convertible Preferred Stock (the “Series E Preferred Stock”) to institutional investors for $1,000 per share or an aggregate subscription of $13.25 million. The number of shares issued to each participant is based on subscription amount multiplied by conversion rate of 1.1111. The Company also incurred offering costs of approximately $410,000, which covers legal and consulting fee.

 

The HCMC Series E Preferred Stock shall have voting rights on as converted basis at the Company’s next stockholders’ meeting. However, as long as any shares of HCMC Series E Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the HCMC Series E Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the HCMC Series E Preferred Stock or alter or amend the Certificate of Designation, (b) increase the number of authorized shares of HCMC Series E Preferred Stock, or (c) enter into any agreement with respect to any of the foregoing. Each share of Series E Preferred Stock shall be convertible, at any time and from time to time at the option of the Holder thereof, into that number of shares of Common Stock (subject to the beneficial ownership limitations). The initial conversion price for the HCMC Series E Preferred Stock shall equal $0.0001.

 

Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary that is not a Fundamental Transaction (as defined in the Certificate of Designation), the holders of HCMC Series E Preferred Stock shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to $1,000 per share of Series E Preferred Stock.

 

Unless earlier converted or extended as set forth below, a holder may require the redemption of all or a portion of the stated value of the HCMC Series E Preferred Stock either (1) six months after closing or (2) the time at which the balance is due and payable upon an event of default.

 

On March 1, 2023, the Company entered into a First Amendment to HCMC Series E Preferred Stock with each purchaser (“Purchaser”) identified as those who participated in the HCMC Series E Preferred Stock, dated as of August 18, 2022. The parties amended the HCMC Preferred Stock related to the conversion payment whereby upon conversion of the Series E Preferred Stock prior to the record date for the Spin-Off, the Company will pay the Purchaser ten percent (10%) of the stated value of the Series E Preferred Stock converted. The record date is May 1, 2023.

 

On May 15, 2023, the Company and the Purchaser entered into the Second Amendment to the Securities Purchase Agreement, pursuant to which the Company agreed to extend the time period for the Conversion Payment eligibility to December 1, 2023. The Company filed an amendment to the Certificate of Designation to make the redemption price of the Preferred Stock (the “Redemption Price”) equal the Stated Value regardless of the date on which it is redeemed. Prior to this amendment, the Redemption Price was discounted by 1% for each month after the seven-month anniversary of the Issue Date that the Purchaser elected not to redeem.

 

On October 30, 2023, the Company entered into a Third Amendment to the Securities Purchase Agreement with its Series E Redeemable Convertible Preferred Stock purchasers. The parties agreed to: (1) set the initial conversion price for the Series E Preferred Stock to be the 5-day volume weighted average price measured using the 5 trading days preceding the purchase of the Series E Preferred Stock, (2) on the 40th calendar day (the “Reset Date”) after the sale of the Series E Preferred Stock, reset the conversion price in the event the closing price of the Class A common stock on such date is less than the initial conversion, (3) have the reset conversion price equal a 10% discount to the 5-day volume weighted average price measured using the 5 trading days preceding the Reset Date; provided, however, in no instance will the conversion price be reset below 30% of the initial conversion price, and (4) amend the date on which the obligation to acquire the Series E Preferred Stock ceases to March 1, 2024.

 

On February 20, 2024, the Company entered into a Fourth Amendment to the Securities Purchase Agreement with its Series E Redeemable Convertible Preferred Stock purchasers, pursuant to which the Company and such parties agreed to amend the date on which the obligation to acquire the Series E Preferred Stock ceases to June 1, 2024.

 

On April 8, 2024, the Company entered into a Fifth Amendment to the Securities Purchase Agreement with its Series E Redeemable Convertible Preferred Stock purchasers, pursuant to which the Company and such parties agreed to amend the Completion Date to August 1, 2024.

 

13

 

 

On July 26, 2024, the Company entered into a Sixth Amendment to the Securities Purchase Agreement with its Series E Redeemable Convertible Preferred Stock purchasers, pursuant to which the Company and such parties agreed to amend the Completion Date to November 1, 2024.

 

On November 27, 2024, the Company entered into a Seventh Amendment to the Securities Purchase Agreement with its Series E Redeemable Convertible Preferred Stock purchasers, pursuant to which the Company and such parties agreed to amend the Completion Date to May 31, 2025.

 

On April 11, 2025, the Company entered into an Eighth Amendment to the Securities Purchase Agreement with its Series E Redeemable Convertible Preferred Stock purchasers, pursuant to which the Company and such parties agreed to amend the Completion Date to October 31, 2025.

 

On October 30, 2025, the Company entered into a Ninth Amendment to the Securities Purchase Agreement with its Series E Redeemable Convertible Preferred Stock purchasers, pursuant to which the Company and such parties agreed to amend the Completion Date to April 1, 2027.

 

On September 1, 2026, the Company redeemed 1,111 shares of Series E Preferred Stock for total cash consideration of approximately $1,055,545. The redemption resulted in a reduction of the carrying value of the preferred stock by $1,111,100 and a corresponding increase to additional paid-in capital of $55,555, representing the excess of the carrying value over the cash paid.

 

As of September 30, 2026, the Company had cumulatively converted 1,585 shares of Series E Preferred Stock into 15,850,000,000 shares of common stock, and had cumulatively redeemed 13,137 shares of Series E Preferred Stock for approximately $13,059,000 in cash. As of September 30, 2026, there were 0 shares of Series E Preferred Stock issued and outstanding.

 

Stock Options and Restricted Stock

 

During the three and nine months ended September 30, 2026 and 2025, no stock options of the Company were exercised into common stock.

 

The Company recognized stock-based compensation of approximately $0 and $1,223,000 during the three months ended September 30, 2026 and 2025, and approximately $0 and $3,368,000 during the nine months ended September 30, 2026 and 2025, respectively in connection with amortization of restricted stock and stock options. Stock based compensation is included as part of total operating expenses in the accompanying unaudited condensed consolidated statements of operations.

 

Warrants Granted for Services

 

On April 24, 2026, the Company entered into a Consulting Agreement with Active Ventures, LLC (the “Consultant”) to provide services related to developing a crypto acquisition strategy over a three-year consulting term. In consideration for these services, the Company granted the Consultant Pre-Funded Warrants to purchase up to 30,000,000,000 shares of common stock, exercisable at $0.0001 per share. The warrants vest in 12 equal tranches of 2,500,000,000 shares each, with Tranche 1 vesting on April 24, 2026, and the remaining tranches vesting at subsequent intervals over 33 months.

 

The warrants were valued at approximately $30,000 in the aggregate based on their grant-date fair value using the Black-Scholes option pricing model. Since the warrants were granted to a nonemployee, the graded vesting method is mandatory under ASC 718. Accordingly, compensation cost for each tranche is recognized over its respective vesting period. For the three and nine months ended September 30, 2026, the Company recognized consulting expenses of approximately $8,000, representing the portions of the tranches earned during the period prior to termination. The expense is included in operating expenses in the accompanying condensed consolidated statements of operations.

 

On September 30, 2026, the Company and the Consultant mutually agreed to terminate the Consulting Agreement. As a result of the termination, all unvested warrants (Tranches 2 through 12) were forfeited. As of September 30, 2026, 2,500,000,000 warrants (representing Tranche 1) remained fully vested and outstanding. No further compensation expense will be recognized related to this agreement.

 

Debt Settlement through Issuance of Common Stock

 

On December 31, 2025, the Company entered into a Stock Purchase and Satisfaction of Debt Agreement with Healthy Choice Wellness Corp. (“HCWC”), a related party. Pursuant to this agreement, the Company issued 43,889,786,222 shares of its common stock to HCWC at a contractual price of $0.00009 per share, in full and final settlement of a related party payable, which had a carrying value of $3,950,080 as of the settlement date. In accordance with the Company’s accounting policy for related party transactions, the payable was extinguished at its carrying amount, and no gain or loss was recognized.

 

On February 1, 2026, the Company entered into a settlement agreement with a vendor to resolve approximately $1.3 million in outstanding accounts payable for past services. Under the terms of the agreement, the total obligation was reduced to $875,000, and the Company issued a non-interest bearing promissory note in that amount to the vendor. The remaining balance of the original obligation was satisfied through a combination of (i) the issuance of 2,000,000,000 shares of the Company’s common stock valued at $0.0001 per share, totaling $200,000, and (ii) the recharacterization of a portion of the obligation as part of a contingent fee arrangement related to ongoing patent litigation.

 

Loss Per Share

 

Basic earnings per share is computed using the weighted average number of common shares outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of common shares outstanding adjusted to include the potentially dilutive effect of stock awards. For the three and nine months ended September 30, 2026 and 2025, diluted EPS is the same as basic EPS because all potentially dilutive securities are anti-dilutive. Under GAAP, diluted EPS must be disclosed even when equal to basic EPS. All potentially dilutive securities were excluded from the diluted EPS calculation because their inclusion would have been anti-dilutive (i.e., reduce the loss per share), which is not permitted under GAAP.

 

The following table summarizes the Company’s securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:

 

   2026   2025 
   As of September 30, 
   2026   2025 
Preferred stock   -    11,111,000,000 
Stock options   67,587,222,200    67,587,222,200 
Restricted stock   -    - 
Pre-Funded Warrants   30,000,000,000    - 
Total   97,587,222,200    78,698,222,200 

 

14

 

 

The following table sets forth the computation of basic and diluted earnings per share attributable to the Company’s stockholders.

 

   2026   2025   2026   2025 
   Three Months Ended September 30,   Nine Months Ended September 30, 
   2026   2025   2026   2025 
                 
NET LOSS  $(315,418)  $(2,076,113)  $

(1,026,977

)  $(6,251,586)
                     
BASIC AND DILUTED WEIGHTED AVERAGE COMMON SHARES   527,156,418,606    481,266,632,384    526,914,660,364    481,266,632,384 
                     
BASIC AND DILUTED NET LOSS PER SHARE  $-   $-   $-   $- 

 

 

NOTE 9. COMMITMENTS AND CONTINGENCIES

 

Legal Proceedings

 

There were two lawsuits in connection with alleged claimed battery defects for an electronic cigarette device. One has been dismissed by the court wherein the plaintiff settled with the Company’s insurance carrier with no economic impact to the Company. In the second lawsuit, as of December 31, 2023, the Company had reached an arrangement with the plaintiff to resolve the matter, limiting potential exposure to $1.5 million which was reflected in accounts payable and accrued expenses, representing management’s estimate of the probable settlement amount based on the current status of discussions. This arrangement was formalized by a signed agreement on July 1, 2024 and the Company has accrued $1.5 million at June 30, 2024. As of May 31, 2025, the Company already paid $1.5 million in full.

 

On September 26, 2023, HCMC filed a patent infringement lawsuit against R.J. Reynolds Vapor Company (“RJR”) in the U.S. District Court for the Middle District of North Carolina in connection with HCMC’s assertions that RJR’s Vuse electronic cigarette infringes one of HCMC’s patents.

 

On November 17, 2023, RJR filed a motion to dismiss the action. HCMC opposed on December 22, 2023.

 

On September 18, 2024, RJR filed an inter partes review of the patent-in-suit at the United States Patent and Trademark Office (“USPTO”).

 

In March 2026, the Patent Trial and Appeal Board issued a decision in favor of RJR in the ongoing patent dispute. On June 1, 2026, HCMC filed an appeal to the ruling in the U.S. Court of Appeals for the Federal Circuit. The appeal is presently pending before the U.S. Court of Appeals for the Federal Circuit.

 

From time to time the Company is involved in legal proceedings arising in the ordinary course of our business. We believe that there is no other litigation pending that is likely to have, individually or in the aggregate, a material adverse effect on our financial condition or results of operations as of September 30, 2026. With respect to legal costs, we record such costs as incurred.

 

NOTE 10. RELATED PARTY TRANSACTIONS

 

Prior to the Spin-Off, HCWC was a subsidiary of HCMC. Following the Spin-Off on September 13, 2024, the Company and HCWC operate as separate, publicly traded companies, though they remain related parties due to common ownership history and ongoing agreements.

 

Due to Related Party

 

Prior to the Spin-Off, there was no intercompany agreement between the Company and HCWC. Management has determined that intercompany receivables and payables will be settled within twelve months after the balance sheet date. As a result, the Company’s intercompany balances are reflected as “due to” or “due from” accounts in the consolidated balance sheets. After the Spin-Off, the Company and HCWC provided services to each other pursuant to the separation agreements to facilitate a smooth transition. The Company had a net due to related party balance of $11,000 and $0 million to HCWC as of September 30, 2026 and December 31, 2025, respectively.

 

Write-off of Related Party Payable

 

During the nine months ended September 30, 2026, a related party payable of $207,195 to HCWC was extinguished. While there is no standalone formal release document, the liability was substantively extinguished in connection with the reverse acquisition of HCWC by Host Digital Infrastructure LLC on September 17, 2026. In accordance with ASC 805 (Business Combinations), HCWC performed a purchase price allocation and determined that its intercompany receivable due from HCMC had a fair value of $0. This formal valuation constitutes a GAAP-compliant determination by the creditor that the asset possesses no future economic benefit and that the claim will not be collected, satisfying the principle of substantive extinguishment under ASC 405-20-40-1.

 

Because HCMC and HCWC remain related parties, the extinguishment of this payable must be evaluated under ASC 470-50-40-2 and ASC 850, which require related-party debt forgiveness to be recorded based on its economic substance rather than its legal form. The substance of this transaction is a capital contribution from a related party, not a gain-generating event.

 

Accordingly, the $207,195 carrying value of the extinguished payable has been credited to Additional Paid-In Capital (APIC) as a capital contribution. This treatment is consistent with the Company’s accounting for the $3,950,080 related-party payable settlement executed on December 31, 2025. No gain or loss was recognized in the condensed consolidated statements of operations for the nine months ended September 30, 2026.

 

15

 

 

Settlement of Related Party Payable

 

On December 31, 2025, the Company entered into a Stock Purchase and Satisfaction of Debt Agreement with HCWC to settle the outstanding related party payable. Pursuant to this agreement, the Company issued 43,889,786,222 shares of its common stock to HCWC in full and final settlement of the payable, which had a carrying value of $3,950,080 as of the settlement date. The shares were issued at a contractual price of $0.00009 per share.

 

In accordance with ASC 850, Related Party Disclosures, and SAB Topic 5.T, transactions involving related parties are recorded based on their substance rather than merely their legal form. Related party transactions cannot be presumed to be carried out on an arm’s-length basis. Accordingly, the payable was extinguished at its carrying amount of $3,950,080, and no gain or loss was recognized. The substance of this transaction is a capital transaction, a conversion of intercompany funding to equity, not a gain-generating event.

 

For disclosure purposes only, the Company determined the fair value of the common stock issued as of December 31, 2025 in accordance with ASC 820, Fair Value Measurement. HCWC, as the investor, performed an impairment assessment of its investment in the Company using a third-party valuation. That assessment, which utilized a multi-method approach including observable and unobservable inputs, concluded that the fair value of the Company’s common stock exceeded HCWC’s carrying value; therefore, no impairment was recorded.

 

Agreements with HCWC

 

The Company entered into several agreements with HCWC that, among other things, affect the separation and govern the relationship of the parties following the Spin-Off. These agreements include:

 

  ● a Separation Agreement that sets forth HCMC’s and HCWC’s agreements regarding the principal actions that both parties take in connection with the Spin-Off and aspects of our relationship following the Spin-Off;
  ● a Transition Services Agreement pursuant to which HCMC and HCWC provide each other specified services on a transitional basis to help ensure an orderly transition following the Spin-Off.
  ● a Tax Matters Agreement (“TMA”) that governs the respective rights, responsibilities and obligations of HCMC and HCWC after the Spin-Off with respect to all tax matters and includes restrictions to preserve the tax-free status of the Spin-Off; and
  ● an Employee Matters Agreement (“EMA”) that addresses employment, compensation and benefits matters, including the allocation and treatment of assets and liabilities arising out of employee compensation and benefits programs in which our employees participated prior to the Spin-Off.

 

Termination of Transition Services Agreement

 

On August 10, 2026, the Company and HCWC entered into a Termination Agreement, which formally terminated the TSA effective as of January 1, 2026. The Termination Agreement provides for a mutual release of any liability or obligation under the TSA from and after the effective date. As a result, no further services will be provided by the Company to HCWC under the TSA. Management determined that the payroll costs primarily benefited HCWC and that the corresponding liability was legally extinguished. Accordingly, during the three months ended June 30, 2026, the Company reclassified the payroll expense and recognized a reduction in operating expenses of $328,373. This reclassification is presented as “Reclassification of payroll expense – TSA termination” in the accompanying condensed consolidated statements of operations.

 

NOTE 11. SUBSEQUENT EVENTS

 

In accordance with FASB ASC 855-10, Subsequent Events, the Company has evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed consolidated financial statements were available to be issued. Based upon this review, the Company has determined that there are no material subsequent events that require disclosure or recognition in the accompanying condensed consolidated financial statements.

 

16

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF CONDENSED CONSOLIDATED OPERATIONS

 

The following discussion and analysis should be read in conjunction with our unaudited interim condensed consolidated financial statements and related notes appearing elsewhere in this report on Form 10-Q. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements. The terms “we,” “us,” “our,” and the “Company” refer to Healthier Choices Management Corp. and its wholly-owned subsidiaries, HCMC Intellectual Property Holdings, LLC and The Vape Store, Inc. (“Vape Store”). All intercompany accounts and transactions have been eliminated in consolidation.

 

Company Overview

 

Healthier Choices Management Corp. is a holding company focused on monetizing its intellectual property through its wholly owned subsidiary, HCMC Intellectual Property Holdings, LLC. The Company seeks to further monetize its patent suite through development and production of its patented products, including the Q-Cup™ technology and Imitine, licensing and royalty agreements, and enforcement actions against infringers of its intellectual property.

 

Through its wholly owned subsidiary HCMC Intellectual Property Holdings, LLC, the Company manages and intends to expand on its intellectual property portfolio.

 

Additionally, the Company markets its patented the Q-Cup™ technology under the vape segment; this patented technology is based on a small, quartz cup called the Q-Cup™, which a customer partially fills with either cannabis or CBD concentrate (approximately 50mg) purchased from a third party. The Q-Cup™ is then inserted into the Q-Cup™ Tank or Globe, that heats the cup from the outside without coming in direct contact with the solid concentrate. This Q-Cup™ technology provides significantly more efficiency and an “on the go” solution for consumers who prefer to vape concentrates either medicinally or recreationally.

 

As disclosed in Note 1 to the condensed consolidated financial statements, the Company entered into a Distribution Agreement on November 27, 2025, to commercialize a new product line, Quitcubes, utilizing the Company’s NatureTine™ ingredient. The distributor is responsible for marketing, customer fulfillment, and website management, while the Company is responsible for manufacturing. The launch was originally anticipated in the first quarter of 2026 but was delayed as the Company established the necessary operational infrastructure. As a result, the Company recorded immaterial net sales from Quitcubes for the three and nine months ended September 30, 2026. Subsequent to quarter end, the Company officially launched the Quitcubes product line in the fourth quarter of 2026. However, initial sales have been de minimis and have not met management’s initial expectations. Management continues to work with the distributor to drive product awareness; however, there can be no assurance that the product line will generate material revenue or positive cash flow in the future.

 

17

 

 

Liquidity

 

The unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern and realization of assets and satisfaction of liabilities in the normal course of business and do not include any adjustments that might result from the outcome of any uncertainties related to our going concern assessment. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The unaudited consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

 

The Company currently and historically has reported net losses and cash outflows from operations. As of September 30, 2026, the Company had cash and cash equivalents of approximately $0.1 million and negative working capital of $1.7 million. The Company’s liquidity needs through September 30, 2026 have been satisfied through financing agreement with private lenders.

 

On March 27, 2026, the Company terminated its prior $5 million credit facility with a private lender, and entered into a new $5 million Sabby Loan Agreement. The Sabby Facility matures on December 31, 2026, bears interest at 12% per annum, and allows for advances from time to time subject to the terms and conditions of the loan agreement. In connection with the Sabby Facility, the Company received an initial advance of $500,000. The remaining $4.5 million is available for future draws.

 

On June 26, 2026, the Company received $50,000 in cash proceeds from Pinz Capital Special Opportunities Fund, LP in connection with a convertible promissory note. The formal loan agreement was executed on July 6, 2026. The note matures May 5, 2030, bears interest at 12% per annum, payable in kind, with principal and interest due in ten equal monthly installments beginning on the third anniversary of issuance, subject to earlier conversion. The proceeds from this note provided additional liquidity to support the Company’s operations.

 

Management has made plans to reduce certain costs and raise the capital needed, however there can be no assurance the Company can successfully implement these plans. The success of these plans is dependent upon various factors, foremost being the ability to reduce outside consulting expenses and the ability to secure additional capital from outside investors. There can be no assurance that such plans will be successful.

 

Management believes that the Company’s cash on hand, together with the availability of up to $4.5 million in additional draws under the Sabby Loan Agreement, and the $50,000 in proceeds received on June 26, 2026 (with the formal loan agreement executed on July 6, 2026), will enable the Company to meet its obligations and capital requirements for at least twelve months from the date these financial statements are issued. Accordingly, no adjustment has been made to the financial statements to account for this uncertainty.

 

Factors Affecting Our Performance

 

We believe the following factors affect our performance:

 

Pending Patent: We have developed, trademarked and are preparing to commercialize additional products. We include product development expenses as part of our operating expenses. In October 2018, we announced the granting of three US patents related to our Q-Cup™ technology. In addition, we have a suite of patent applications pending in the United States. There is no assurance that we will be awarded patents for any of these pending patent applications. There is no assurance that we can monetize the patents.

 

Manufacturing: We have no manufacturing capabilities and do not intend to develop any manufacturing capabilities. Third party manufacturers make our products to meet our design specifications. We depend on third party manufacturers for our vaporizer e-liquid and accessories. Any interruption in supply and or consistency of our products may harm our relationships and reputation with customers, and have a material adverse effect on our business, results of operations and financial condition. In order to minimize the risk of supply interruption, we currently utilize several third-party manufacturers to manufacture our products to our specifications.

 

Results of Operations

 

The following table sets forth our unaudited condensed consolidated Statements of Operations for the three months ended September 30, 2026 and 2025 that is used in the following discussions of our results of operations:

 

   Three Months Ended September 30,   2026 to 2025 
       2025   Change $ 
SALES, NET  $76   $199   $(123)
                
COST OF SALES   18    -    18 
                
GROSS PROFIT   58    199    (141)
                
OPERATING EXPENSES   302,339    2,085,196    (1,782,857)
                
LOSS FROM OPERATIONS   (302,281)   (2,084,997)   1,782,716 
                
OTHER INCOME (EXPENSE)               
Other expense, net   (136)   -    (136)
Interest (expense) income, net   (13,001)   8,884    (21,885)
TOTAL OTHER INCOME (EXPENSE), NET   (13,137)   8,884    (22,021)
                
NET LOSS  $(315,418)  $(2,076,113)  $1,760,695 

 

18

 

 

Net sales and cost of sales were de minimis for the three months ended September 30, 2026 and 2025. The Company closed all its brick-and-mortar retail vape stores, as management had shifted its retail sales focus to the wholesale and online channel. The sales and cost of sales for the three months ended September 30, 2026 and 2025 continued to be significantly impacted by the inability to bring new products to market via distribution.

 

Total operating expenses decreased by approximately $1.8 million to $0.3 million for the three months ended September 30, 2026 compared to $2.1 million for the same period in 2025. The decrease was driven by a $1.1 million reduction in stock-based compensation expense and a $0.7 million reduction in general operating costs, including payroll and benefits, professional fees, and taxes, licenses and permits, reflecting management’s ongoing cost-reduction initiatives and the termination of the Transition Services Agreement (TSA) with HCWC.

 

Total other income (expense), net was approximately $13,000 in expense for the three months ended September 30, 2026, compared to $9,000 in income for the same period in 2025. This represents an unfavorable swing of approximately $22,000. The change was driven primarily by a $22,000 shift in interest, moving from net interest income of $9,000 in 2025 to net interest expense of $13,000 in 2026. This increase in interest expense is largely related to the new loan agreements and convertible notes entered into during 2026.

 

The following table sets forth our unaudited condensed consolidated Statements of Operations for the nine months ended September 30, 2026 and 2025 that is used in the following discussions of our results of operations:

 

   Nine Months Ended September 30,   2026 to 2025 
   2026   2025   Change $ 
SALES, NET  $76   $2,979   $(2,903)
                
COST OF SALES   18    25,312    (25,294)
                
GROSS PROFIT   58    (22,333)   22,391 
                
OPERATING EXPENSES   1,352,731    6,235,686    (4,882,955)
                
RECLASSIFICATION OF PAYROLL EXPENSE – TSA TERMINATION   (328,373)   -    (328,373)
                
LOSS FROM OPERATIONS   (1,024,300)   (6,258,019)   5,233,719 
                
OTHER INCOME (EXPENSE)               
Loss on disposal of asset   -    (22,809)   22,809 
Other income, net   12,364    3,070    9,294 
Interest (expense) income, net   (15,041)   26,172    (41,213)
TOTAL OTHER INCOME (EXPENSE), NET   (2,677)   6,433    (9,110)
                
NET LOSS  $(1,026,977)  $(6,251,586)  $5,224,609 

 

Net sales and cost of sales were de minimis for the nine months ended September 30, 2026 and 2025. The Company closed all its brick-and-mortar retail vape stores, as management had shifted its retail sales focus to the wholesale and online channel. The sales and cost of sales for the nine months ended September 30, 2026 and 2025 continued to be significantly impacted by the inability to bring new products to market via distribution.

 

Total operating expenses decreased by approximately $4.9 million to $1.4 million for the nine months ended September 30, 2026 compared to $6.2 million for the same period in 2025. This significant decrease was primarily driven by a $3.4 million reduction in stock-based compensation expense, and a $1.4 million reduction in general operating costs, including payroll and benefits, professional fees, and taxes, licenses and permits, reflecting management’s ongoing cost-reduction initiatives. These decreases were partially offset by an approximately $90,000 non-cash impairment charge recorded in the third quarter of 2026 to fully write off the remaining net carrying value of the Company’s patents (as discussed in Note 6). The $1.4 million in total operating expenses for 2026 is net of a $328,373 reduction (presented as “Reclassification of payroll expense — TSA termination” on the statement of operations) resulting from the termination of the Transition Services Agreement (TSA) with HCWC in the second quarter of 2026.

 

Total other income (expense), net was approximately $3,000 for the nine months ended September 30, 2026, compared to total other income, net of approximately $6,000 for the same period in 2025. This unfavorable change of approximately $9,000 was primarily driven by a $41,000 unfavorable swing in interest, shifting from net interest income of $26,000 in 2025 to net interest expense of $15,000 in 2026, due to the new loan agreements and convertible notes entered into during the current year. This decrease in total other income was partially offset by the absence of a $23,000 loss on asset disposal that occurred in the prior year period, as well as a $9,000 increase in other income.

 

19

 

 

Liquidity and Capital Resources

 

The following table and the discussion present the Company’s cash activities on continuing basis for nine months ended September 30, 2026 and 2025:

 

   Nine Months Ended September 30, 
   2026   2025 
Net cash (used in) provided by:          
Operating activities  $(645,421)  $(3,058,181)
Investing activities   -    - 
Financing activities   (512,916)   2,532,979 
Total net decrease in cash  $(1,158,337)  $(525,202)

 

Our net cash used in operating activities of approximately $0.6 million for the nine months ended September 30, 2026 resulted from a net loss of $1.0 million, adjusted by a net non-cash gain of $140,000 and a net increase of $242,000 from changes in operating assets and liabilities.. Our net cash used in operating activities of approximately $3.1 million for the nine months ended September 30, 2025 resulted from a net loss of $6.3 million, offset by a non-cash adjustment of $3.4 million and a net cash change of $0.2 million from changes in operating assets and liabilities.

 

There was no cash used in investing activities for the nine months ended September 30, 2026 and 2025.

 

The net cash used in financing activities of $0.5 million for the nine months ended September 30, 2026 was primarily due to $0.5 million in cash proceeds from the Sabby loan advance and $50,000 in cash proceeds from the convertible note received on June 26, 2026 (with the formal loan agreement executed on July 6, 2026). These inflows were offset by the $1.1 million cash payment for the Series E preferred stock redemption. The net cash provided by financing activities of $2.5 million for the nine months ended September 30, 2025 is primarily due to $3.0 million net transfers from HCWC and $0.5 million cash payment of the credit line.

 

At September 30, 2026 and December 31, 2025, we did not have any material financial guarantees or other contractual commitments with vendors that are reasonably likely to have an adverse effect on liquidity.

 

Our cash balances are kept liquid to support our operations. Most of our cash and cash equivalents are concentrated in one financial institution and is generally in excess of the FDIC insurance limit. The Company has not experienced any losses on its cash. The following table presents the Company’s cash position as of September 30, 2026 and December 31, 2025.

 

   September 30, 2026   December 31, 2025 
Cash and cash equivalents  $82,151   $1,140,488 
Total assets  $171,508   $1,467,870 
Cash and cash equivalents as a percentage of total assets   47.9%   77.7%

 

The Company reported a net loss from continuing operation of $1.0 million for the nine months ended September 30, 2026. The Company also had negative working capital of $1.7 million. The Company expects to continue incurring losses for the foreseeable future.

 

The Company anticipates its current cash and its ability to draw from the $5 million credit line with private lender will be sufficient to meet projected operating expenses for the foreseeable future through at least twelve months from the issuance of the consolidated financial statements.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements.

 

Critical Accounting Estimates

 

Our management’s discussion and analysis of financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to exercise considerable judgment with respect to establishing sound accounting policies and in making estimates and assumptions that affect the reported amounts of our assets and liabilities, our recognition of revenues and expenses, and disclosure of commitments and contingencies at the date of the condensed consolidated financial statements.

 

We base our estimates on our historical experience, knowledge of our business and industry, current and expected economic conditions, the attributes of our products, the regulatory environment, and in certain cases, the results of outside appraisals. These estimates include useful lives and valuation/impairment of long-lived assets and intangible assets, deferred taxes and related valuation allowances, the fair value of warrants issued in connection with debt agreements, allocation of corporate general expenses, and the valuation of the assets and liabilities acquired in business combinations.

 

We periodically re-evaluate our estimates and assumptions with respect to these judgments and modify our approach when circumstances indicate that modifications are necessary. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.

 

While we believe that the factors we evaluate provide us with a meaningful basis for establishing and applying sound accounting policies, we cannot guarantee that the results will always be accurate. Since the determination of these estimates requires the exercise of judgment, actual results could differ from such estimates.

 

20

 

 

Seasonality

 

We do not consider our business to be seasonal.

 

Cautionary Note Regarding Forward-Looking Statements

 

This report includes forward-looking statements including statements regarding retail expansion, the future demand for our products, the transition to vaporizer and other products, competition, the adequacy of our cash resources and our authorized Common Stock, and our continued ability to raise capital.

 

The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.

 

The results anticipated by any or all of these forward-looking statements might not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include our future common stock price, customer acceptance of our products, and proposed federal and state regulation. We undertake no obligation to publicly update or revise any forward-looking statements, whether as the result of new information, future events or otherwise.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable to smaller reporting companies.

 

ITEM 4. CONTROLS AND PROCEDURES

 

We are required to report under Section 404(a) of Sarbanes-Oxley regarding the effectiveness of our internal control over financial reporting.

 

Evaluation of Disclosure Controls and Procedures

 

Our management, including our Principal Executive Officer and Principal Financial Officer, carried out an evaluation on internal controls as of September 30, 2026 in regard to the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, or the Exchange Act. As a result of the evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this report.

 

The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting. Under the supervision and with the participation of the Company’s management, including the Chief Executive Officer and Chief Financial Officer, the Company evaluated the effectiveness of the design and operation of its internal control over financial reporting based on the framework established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer concluded that the Company’s internal control over financial reporting was ineffective as of September 30, 2026 and noted the material weaknesses as follows:

 

  ● Failure to have properly documented and designed disclosure controls and procedures and testing of the operating effectiveness of our internal control over financial reporting.

 

21

 

 

  ● Segregation of duties due to lack of personnel.
     
  ● The Company had ineffective design, implementation and, operation of controls over logical access, program change management, and vendor management controls. The Company controls on IT should have included the following:

 

  ○ Appropriate restrictions that would adequately prevent users from gaining inappropriate access to the financially relevant systems.
     
  ○ IT program and data changes affecting the Company’s financial IT applications and underlying accounting records, should be identified, tested, authorized and implemented appropriately to validate that data produced by its relevant IT system(s) were complete and accurate.
     
  ○ Obtaining and reviewing key third party service provider SOC reports.

 

Our management concluded that considering internal control deficiencies that, in the aggregate, rise to the level of material weaknesses, we did not maintain effective internal control over financial reporting as of September 30, 2026 based on the criteria set forth in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).

 

Planned Remediation

 

Management continues to work to improve its controls related to our material weaknesses listed above. In order to achieve the timely implementation of the above, management has commenced the following actions and will continue to assess additional opportunities for remediation on an ongoing basis:

 

  ● Continuing to increase headcount across the Company, with a particular focus on hiring individuals with strong internal control backgrounds and inventory expertise.
     
  ● Establishing policies and procedures in the IT area to mitigate data breach, unauthorized access and address segregation of duties, as well as review key third party service provider SOC reports.

 

We are currently working to improve and simplify our internal processes and implement enhanced controls, as discussed above, to address the material weaknesses in our internal control over financial reporting and to remedy the ineffectiveness of our disclosure controls and procedures. These material weaknesses will not be considered to be remediated until the applicable remediated controls are operating for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.

 

Changes in Internal Controls over Financial Reporting

 

Except as detailed above, during the quarter ended September 30, 2026, there were no significant changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

 

22

 

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

There were two lawsuits in connection with alleged claimed battery defects for an electronic cigarette device. One had been dismissed by the court wherein the plaintiff settled with the Company’s insurance carrier with no economic impact to the Company. In the second lawsuit, as of December 31, 2023, the Company had reached an arrangement with the plaintiff to resolve the matter, limiting potential exposure of the Company to $1.5 million which was reflected in accounts payable and accrued expenses, representing management’s estimate of the probable settlement amount based on the current status of discussions. This arrangement was formalized by a signed agreement on July 1, 2024 and the Company accrued $1.5 million at June 30, 2024. As of May 31, 2025, the Company already paid $1,500,000 in full.

 

On September 26, 2023, HCMC filed a patent infringement lawsuit against R.J. Reynolds Vapor Company (“RJR”) in the U.S. District Court for the Middle District of North Carolina in connection with HCMC’s assertions that RJR’s Vuse electronic cigarette infringes one of HCMC’s patents.

 

On November 17, 2023, RJR filed a motion to dismiss the action. HCMC opposed on December 22, 2023.

 

On September 18, 2024, RJR filed an inter partes review of the patent-in-suit at the United States Patent and Trademark Office (“USPTO”).

 

In March 2026, the Patent Trial and Appeal Board issued a decision in favor of RJR in the ongoing patent dispute. On June 1, 2026, HCMC filed an appeal to the ruling in the U.S. Court of Appeals for the Federal Circuit. The appeal is presently pending before the U.S. Court of Appeals for the Federal Circuit.

 

From time to time the Company is involved in legal proceedings arising in the ordinary course of our business. We believe that there is no other litigation pending that is likely to have, individually or in aggregate, a material adverse effect on our financial condition or results of operations as of September 30, 2026. With respect to legal costs, we record such costs as incurred.

 

ITEM 1A. RISK FACTORS.

 

Not Applicable.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

Not Applicable.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not Applicable.

 

ITEM 5. OTHER INFORMATION.

 

Not Applicable.

 

ITEM 6. EXHIBITS.

 

See the exhibits listed in the accompanying “Index to Exhibits.”

 

23

 

 

INDEX TO EXHIBITS

 

Exhibit       Incorporated by Reference   Filed or Furnished
No.   Exhibit Description   Form   Date   Number   Herewith
10.1   Loan Agreement, dated as of March 27, 2026, among Healthier Choices Management Corp., and Sabby Volatility Warrant Master Fund, Ltd.   8-K   4/3/2026   10.1    
10.2   Letter Agreement, dated March 27, 2026, by and between HCMC and Hal Mintz   8-K   4/3/2026   10.1    
31.1   Certification of Principal Executive Officer (302)               Filed
31.2   Certification of Principal Financial Officer (302)               Filed
32.1   Certification of Principal Executive Officer (906)               Furnished *
32.2   Certification of Principal Financial Officer (906)               Furnished *
101.INS   Inline XBRL Instance Document               Filed
101.SCH   Inline XBRL Taxonomy Extension Schema Document               Filed
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document               Filed
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document               Filed
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document               Filed
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document               Filed
104   Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)               Filed

 

* This exhibit is being furnished rather than filed and shall not be deemed incorporated by reference into any filing, in accordance with Item 601 of Regulation S-K.

 

24

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  HEALTHIER CHOICES MANAGEMENT CORP.
     
Date: November 13, 2026 By: /s/ Jeffrey Holman
    Jeffrey Holman
    Chief Executive Officer
     
Date: November 13, 2026 By: /s/ John Ollet
    John Ollet
    Chief Financial Officer

 

25

 

Keep reading